Plain-English translation of NCT05844501 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atrial Fibrillation research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing ondansetron, a medication that's already used to treat nausea, to see if it can help control atrial fibrillation—a condition where your heart beats irregularly. Researchers believe this medication may help reduce how often your heart goes into an irregular rhythm and help control your heart rate. You would take the medication twice daily for 28 days leading up to a planned heart ablation procedure (a treatment to fix the irregular heartbeat).
Current treatments for atrial fibrillation don't work well enough for many people or cause side effects that are hard to tolerate. This medication may offer a safer, more effective option by targeting a specific electrical process in the heart that contributes to irregular rhythms.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you'll be randomly assigned to take either the medication or a placebo (a dummy pill) twice daily for 28 days. Your treatment will start several weeks before your scheduled ablation procedure and will be finished at least 3 days before the procedure. During the study, you'll wear special adhesive skin patches (ECG monitors) for 14 days at a time to continuously record your heart rhythm and measure how much time your heart spends in an irregular rhythm.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States